High Tide joins U.S. National Compassionate Care Council | HITI Stock News

WHY IT MATTERS: Patients relying on medical cannabis for serious conditions may see improved access, more consistent product standards, and stronger legal protections if compassionate care policy reforms move forward at the federal level. CLINICAL OVERVIEW: Efforts to modernize medical cannabis policy at a national level reflect a growing recognition that patients deserve structured, evidence-informed access to cannabinoid therapies rather than navigating a fragmented and inconsistent regulatory landscape. Compassionate care frameworks have historically served as critical pathways for patients with serious or treatment-resistant conditions to access medications outside of standard channels.

Read More

US Cannabis Rescheduling: A Victory or a Federal Trap?

WHY IT MATTERS: If rescheduling leads to FDA-only pathways for legal cannabis, patients currently using state-regulated medical cannabis products could face disruptions in access, changes in available formulations, or higher costs as the market adjusts to new federal compliance requirements. CLINICAL OVERVIEW: The rescheduling of cannabis from Schedule I to Schedule III represents a significant federal policy shift, but it raises complex questions about whether this move truly expands patient access or instead creates a regulatory bottleneck by funneling cannabis into an FDA approval framework that most existing products cannot meet. From a clinical perspective, rescheduling could legitimize cannabis medicine in the eyes of insurers and institutional healthcare systems, yet it risks disrupting the state-regulated markets that currently serve millions of patients.

Read More